Vancouver, British Columbia–(Newsfile Corp. – August 3, 2022) – Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E81) (“APC” or the “Company”) is pleased to announce that the United States Patent and Trademark Office has issued a patent to its US subsidiary, Advanced Proteome Therapeutics Inc. (“APTI”).

On August 2, 2022, APTI was issued U.S. Patent No. 11,400,165 titled ‘Composition and method for modifying polypeptides’. The patent covers highly site-selective antibody conjugate compositions produced with APTI’s two-step conjugation technology including the half-product of the first step and final antibody-drug conjugate (ADC) product of the second step. The claims broadly cover antibodies as a class and different classes of payloads including toxins, drugs and chelators. The patent term, including patent term adjustment, is expected to extend into November 2039. This is the first patent issued under US patent application 16/180,960. APTI is continuing to pursue expanded claims and additional patents within the initial application in order to create additional layers of intellectual property protection.

Dr. Benjamin Krantz, President and CEO of APTI commented, “The issuance of this patent is a critical milestone for APTI. The patent provides market exclusivity to highly site-selective ADC compositions that are created with our two-step antibody conjugation approach. This protection greatly enhances our ability to monetize our invention and increases our attractiveness to potential collaborators. This is another step forward in our 2022 plan and I look forward to other successes in the near future.”

Advanced Proteome Therapeutics Corporation, through its subsidiary, Advanced Proteome Therapeutics Inc., has invented proprietary protein conjugation technology which enables the development of superior antibody-drug conjugates through improved site-specific labeling, drug-antibody ratio control and enabling of combination payloads. The technology has compelling pre-clinical data demonstrating improved homogeneity and increased in-vivo potency relative to current state of the art linker technology. The Company believes that the technology will enable the development of safer and more potent antibody-drug conjugate therapeutics and is pursuing licensing and partnership opportunities to advance development and create shareholder value.

Advanced Proteome Therapeutics Corporation
Paul Woodward
President and CEO
Tel: 604 690-3797

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains forward-looking statements relating to the future operations of the Company and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “intends”, “anticipates”, “expects” and similar expressions. All statements other than statements of historical fact included in this release, including, without limitation, statements regarding the future plans and objectives of the Company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations are risks detailed from time to time in the filings made by the Company with securities regulators.

Readers are cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties and other factors, many of which are beyond the control of the Company. As a result, the Company cannot guarantee that any forward-looking statement will materialize and readers should not place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will only update or revise publicly any of the included forward-looking statements as expressly required by Canadian securities law.